<DOC>
	<DOCNO>NCT02167451</DOCNO>
	<brief_summary>The purpose determine addition Maraviroc standard transplant regimen reduce incidence graft versus host disease child young adult stem cell transplant .</brief_summary>
	<brief_title>Maraviroc GVHD Prophylaxis Transplant Recipients</brief_title>
	<detailed_description>In first stage , drug level obtain establish appropriate dosing . In second stage study investigator study effect use Maraviroc patient .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Ages 5 year &lt; /= 40 year All diagnosis Marrow cord blood All conditioning regimens Patient must plan receive calcineurin inhibitor ( cyclosporine tacrolimus ) together steroid , methotrexate mycophenolate mofetil GVHD prophylaxis . Documented anaphylaxis Maraviroc Ex vivo Tcell ( type white blood cell ) deplete graft Abnormal Alanine Aminotransferase ( ALT ) ( &gt; /=10X ULN ) day 3 . ( Assessed study enrollment confirm prior first dose maraviroc . )</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>GVHD prevention</keyword>
</DOC>